Zoekresultaten - You searched for Antibodies

55 results

VIB: Edible antibodies to treat and prevent gastrointestinal disorders

Read more

Argenx awarded €2.5 million VLAIO grant to identify novel therapeutic antibodies

Read more

V-Bio Ventures leads AgomAb Therapeutics’ 21m EUR series A financing round

Read more

Argenx announces expansion of its pipeline with addition of complement-targeted ARGX-117 for treatment of severe autoimmune diseases

Read more

argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe

Read more

argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia

Read more

ThromboGenics Achieves Important Milestone in the Development of THR-149

Read more

argenx files registration statement for a proposed public offering in the United States

Read more

argenx announces results of Annual General Meeting 2017

Read more

argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis

Read more

argenx launches Phase II proof-of-concept clinical trial of ARGX-113 for the treatment of pemphigus vulgaris

Read more

Ablynx appoints dr. Robert Friesen as Chief Scientific Officer

Read more

Confo Therapeutics is awarded a EUR 1M grant to increase its screening capabilities

Read more

argenx reports first quarter 2018 financial results and provides business update

Read more

argenx receives milestone payment from strategic collaboration with Shire

Read more

Bone Therapeutics announces final results from Phase I/IIA ALLOB delayed-union fracture study

Read more

Bone Therapeutics announces appointment of Linda Lebon as Chief Regulatory Officer

Read more

V-Bio Ventures leads Camel-IDS EUR 37m Series A financing to develop cancer targeted radiopharmaceuticals

Read more

argenx and Halozyme enter global collaboration and license agreement for ENHANZE® technology

Read more

argenx announces first patient dosed in Phase II proof-of-concept study of ARGX-113 for the treatment of primary immune thrombocytopenia

Read more

Specialized blood vessels enhance tumor-fighting immunotherapy

Read more

argenx reports first quarter 2017 financial results and provides business update

Read more

argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in myasthenia gravis

Read more

FairJourney Biologics announces an innovative technology to discover antibody molecules in full therapeutic format

Read more

Biocartis Group NV: MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer

Read more

Researchers gain new insights into the formation of non-pathological amyloids

Read more

argenx presents full data from ARGX-111 Phase Ib study in patients with advanced cancers over-expressing the MET protein

Read more

BioInvent and ThromboGenics Amending Long-Standing Monoclonal Antibody Development Agreement

Read more

Delphi Genetics receives GMP accreditation for plasmid DNA bioproduction

Read more

argenx announces publication of preclinical data supporting the therapeutic potential of SIMPLE AntibodyTM ARGX-116

Read more

Bone Therapeutics reports strong interim results from ALLOB® Phase IIA spinal fusion study

Read more

Bone Therapeutics announces all patients meet primary endpoint in ALLOB® Phase I/IIA delayed-union study interim analysis

Read more

argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune thrombocytopenia

Read more

Camel-IDS appoints Ruth Devenyns as Chief Executive Officer

Read more

Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL-17C antibody MOR106 in atopic dermatitis patients

Read more

MyCartis appoints Philippe Stas as CEO

Read more

argenx launches Phase I trial with subcutaneous formulation of ARGX-113

Read more

argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis

Read more

Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as late-breaking abstract at the American Academy of Dermatology (AAD) meeting in San Diego

Read more

argenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meeting

Read more

argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting

Read more

Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients

Read more

argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis

Read more

argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation

Read more

MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner

Read more

argenx announces publication of full data from Phase 1 healthy volunteer study of efgartigimod in Journal of Clinical Investigation

Read more

argenx receives feedback from Japan's PMDA on Phase 3 clinical trial

Read more

MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 with pharma partner

Read more

Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106

Read more

argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia

Read more

argenx awarded €2.6 million VLAIO grant to explore new applications of ABDEG technology

Read more

Novosanis acquired by Orasure Technologies Inc

Read more

Novosanis enters into distribution deal with Fujirebio

Read more

Next-Generation Antibodies and Protein Analysis (2nd Edition) - A VIB TOOLS & TECHNOLOGIES CONFERENCE

Read more

de clercq & partners annual ip seminar

Read more